Patent US4232037A successfully refreshed from Google Patents.
US4232037A
Expired / Lapsed
US
⏱️ 0.0 years remaining
2,6-Dialkoxybenzamides, intermediates, pharamaceutical compositions and methods for treatment of psychotic disorders
Assignee: AstraZeneca AB
•
Filing: 1979-03-08
•
Granted: 1980-11-04
•
Expires: 1999-03-08
Abstract
Abstract A compound of the formula <IMAGE> I wherein R1 is an alkyl group with 1-3 carbon atoms, R2 and R3 are the same or different and each is hydrogen, chlorine or bromine; and pharmaceutically acceptable salts and optical isomers thereof; methods and intermediates for the preparation of the compounds; pharmaceutical preparations containing them and their medical use for the treatment of psychoses.
Inventors
- 👤 Gosta L. Florvall
- 👤 Sven O. Ogren
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 21:54
CPC Classifications
C; C07; C07D; C07D207/00; C07D207/02; C07D207/04; C07D207/08; C07D207/09; A; A61; A61P; A61P25/00; A61P25/18; C07C; C07C51/00; C07C51/347; C07C51/363
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
44 words
A compound of the formula ##STR10## or a pharmaceutically acceptable salt thereof, in which formula R 1 represents an alkyl group with 1-3 carbon atoms, R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom.
Claim 2
Dependent Claim
44 words
A compound of the formula ##STR10## or a pharmaceutically acceptable salt thereof, in which formula R 1 represents an alkyl group with 1-3 carbon atoms, R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom.
Claim 3
Dependent Claim
54 words
A compound according to claim 1 with the formula I wherein R 1 is an alkyl group with 1-3 carbon atoms and R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom, provided that R 2 is chlorine or bromine when R 3 is hydrogen.
Claim 4
Dependent Claim
37 words
A compound according to claim 1 with the formula I wherein R 1 is a methyl group and R 2 and R 3 are the same or different and each represents a chlorine or a bromine atom.
Claim 5
Dependent Claim
19 words
A compound according to any of claims 1, 2 or 3 in the form of a substantially pure stereoisomer.
Claim 6
Dependent Claim
74 words
A pharmaceutical preparation which comprises as active ingredient at least one compound of the formula ##STR11## or a pharmaceutically acceptable salt thereof, in an amount effective to block the central dopamine receptors of the brain in which formula R 1 represents an alkyl group with 1-3 carbon atoms, R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom, in association with a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
74 words
A pharmaceutical preparation which comprises as active ingredient at least one compound of the formula ##STR11## or a pharmaceutically acceptable salt thereof, in an amount effective to block the central dopamine receptors of the brain in which formula R 1 represents an alkyl group with 1-3 carbon atoms, R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom, in association with a pharmaceutically acceptable carrier.
Claim 8
Dependent Claim
34 words
A pharmaceutical preparation comprising as active ingredient an amount effective to block the dopamine receptors of the brain of a compound according to claims 2 or 3 in association with a pharmaceutically acceptable carrier.
Claim 9
Dependent Claim
44 words
A pharmaceutical preparation which comprises as an active ingredient an amount effective to block the dopamine receptors of the brain of a compound according to claims 2 or 3 in the form of a substantially pure stereoisomer in association with a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
11 words
A pharmaceutical preparation according to claim 5 in dosage unit form.
Claim 11
Dependent Claim
40 words
A pharmaceutical preparation which comprises as an active ingredient an amount effective to block the dopamine receptors of the brain of a compound according to claims 2 or 3 in association with a pharmaceutically acceptable carrier in dosage unit form.
Claim 12
Dependent Claim
48 words
A pharmaceutical preparation which comprises as an active ingredient an amount effective to block the dopamine receptors of the brain of a compound according to claims 2 or 3 in the form of a substantially pure stereoisomer in association with a pharmaceutically acceptable carrier in dosage unit form.
Claim 13
Independent Claim
70 words
A method for the treatment of psychoses in man, characterized by the administration to a host in need of such treatment of an effective amount of a compound of the formula ##STR12## or a pharmaceutically acceptable salt thereof, in which formula R 1 represents an alkyl group with 1-3 carbon atoms, R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom.
Claim 14
Independent Claim
70 words
A method for the treatment of psychoses in man, characterized by the administration to a host in need of such treatment of an effective amount of a compound of the formula ##STR12## or a pharmaceutically acceptable salt thereof, in which formula R 1 represents an alkyl group with 1-3 carbon atoms, R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom.
Claim 15
Dependent Claim
38 words
A method for the treatment of psychoses according to claim 11, characterized by the administration to a host in need of such treatment of an effective amount of a compound according to any of claims 2 or 3.
Claim 16
Independent Claim
51 words
A method for the treatment of psychoses in man characterized by the administration to a host in need of such treatment of an amount effective to block the dopamine receptors of the brain of a compound according to claims 1, 2 or 3 in the form of a substantially pure stereoisomer.
References Cited (Backward Citations)
DD67123A
Cited
US3342826A
Cited
BE695272A
Cited
US3862139A
Cited
DE2459221A1
Cited
US4029673A
Cited
DE2556457A1
Cited
US4021567A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-11-04 | 1984-05-05 | 1984-11-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-11-04 | 1988-05-05 | 1988-11-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-11-04 | 1992-05-05 | 1992-11-04 | $7700.00 | Window Closed / Lapsed |